Financial News
Written by: Ou Jiajun
2021-01-25 13:49
Last update date: 2021-01-25 13:49
The IPO market is very lively this week. In addition to Kuaishou (1024), which is the fastest IPO on Tuesday, there are also five new pharmaceutical stocks (see the figure below for details) or the IPO will be launched this week. Are all six IPOs selected?
Listen to the experts!
Pictures:
1. Kuaishou Technology
Kuaishou’s listing in Hong Kong will become the “first share of short video”, attracting ten cornerstone investors before listing, including Tencent (0700), Sequoia Capital, Baidu, Temasek, Boyu Capital, Morningside Capital, etc., accounting for the scale of fund-raising About 40%.
In the first nine months of last year, the average daily active users of Kuaishou reached 305 million, and the average daily usage time per daily active user exceeded 86 minutes; the average monthly active users reached 769 million.
Funds raised: US$5.5 billion to US$6 billion (approximately HK$42.63 billion to 46.5 billion)
2. Minimally Invasive Heart Pass
MicroPort Xintong is a medical device company focusing on the field of heart valve diseases. However, the company has only one TAVI (transcatheter aortic valve implantation) product-VitaFlowTM, which has achieved commercial revenue and has not yet achieved profitability.
Amount of funds raised: US$300 million (approximately HK$2.34 billion) will be raised
3. Become Medical
Beikang Medical is mainly engaged in medical devices in the field of reproduction, and its main products are test-tube baby genetic testing kits.
Revenue in the first six months of last year increased by 20% year-on-year to RMB 32.165 million.
Funds raised: up to 250 million US dollars (about 1.95 billion Hong Kong dollars)
Four, Jianbei Miao Miao
Jianbei Miaomiao is a health care product company spun off by Jacobson. Its main source of income comes from branded medicines, health care products and branded Chinese medicines. Its products are mainly located in Greater China, Southeast Asia and other selected countries.
Amount of funds raised: Unknown
5. Nuohui Health
Nuohui Health was established in 2015, focusing on early home screening and genetic testing services for high-incidence cancers. Currently, it has launched products for bowel cancer, cervical cancer, gastric cancer and other diseases. The company’s vision is to achieve cancer prevention and treatment through screening and early detection. cure.
As of the end of June last year, the company's loss expanded to 550 million yuan, mainly due to losses from changes in the fair value of preferred stocks.
Funds raised: approximately US$300 million (approximately HK$2.34 billion)
VI. Saisheng Pharmaceutical
Saisheng Pharmaceutical is a California-based pharmaceutical research and development company focusing on the treatment of major and special diseases. It was listed on the Nasdaq in 1992. In 2017, it was invested by Telford Capital, Bank of China Group, Dinghui Investment, Shangda Capital and The consortium formed by Boying Investment was privatized for $607 million.
Amount of funds raised: 500 million US dollars (about 3.9 billion Hong Kong dollars)
Sir Nie: The first choice is Kuaishou> Minimally Invasive Heart Tong> Nuohui
Independent stock commentator Nie Zhenbang pointed out that Kuaishou is the first choice for many new stocks because its short video concept is scarce in the Hong Kong stock market.
As for the other new pharmaceutical stocks, he pointed out that it can be seen from the actual IPO size. If the IPO size is less than 150 million shares, or even less than 100 million shares, subtracting the number of subscriptions from cornerstone investors, it means that the amount of outstanding stock is very small, that is, the attraction of speculation Will be higher.
From the perspective of cornerstone investors and industry prospects, he believes that MicroPort will be the first choice. There are regular B-share customers such as Qingchi Capital and Hillhouse Capital; the next choice is Nuohui Health, because the company’s business is related to cancer and there is Softbank , Qiming Venture Capital and other leading investment blessings, giving investors greater confidence.
As for Saisheng Pharmaceutical, whose products also involve cancer drugs, Nie Sir pointed out that its industry positioning is not solely focused on cancer-related treatments, but also other critical illness and infection areas. Part of its revenue is also related to the new crown vaccine, but it is not ruled out because of company partners. One is Pfizer. If Pfizer has vaccine-related news in the future, Saisheng Pharmaceutical will also have the opportunity to be hyped by the market.
IPO new shares listed new shares Kuaishou Beikang Medical Health Pei Miao Miao Nuohui Health Saisheng Pharmaceutical Micro Invasive